Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Updated January Presentation

<< Previous

Bullboard Posts

Next >>

Comment by gudisgoodon Jan 17, 2022 3:47am

100 Views

Post# 34323420

RE:RE:Updated January Presentation

Snowballgrowth wrote:

EbbFlow88 wrote: Shares outstanding as of Dec. 31st now showing 117.8M Shares outstanding. Since, I've bought Knight my % ownership has increased by almost 16%. Pretty wild.

This is very important. We all own 16 % more.

If the numbers in my Excel spreadsheet are correct, we had around 130M shares outstanding at the end of 2020, and now 117.8M at the end of 2021. That's more than a 9% decrease within a year.

Again, IF my Excel numbers are correct, in 2019 and 2020 the decreases were 5% and 4%, respectively.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”